Literature DB >> 27080180

Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Shyamsunder R Joolakanti1, Justin R Nickell2, Venumadhav Janganati1, Guangrong Zheng1, Linda P Dwoskin2, Peter A Crooks3.   

Abstract

A series of lobelane and GZ-793A analogues that incorporate aromatic 4-hydroxy and 4-(2-fluoroethoxy) substituents were synthesized and evaluated for inhibition of [(3)H]dopamine (DA) uptake at the vesicular monoamine transporter-2 (VMAT2) and the dopamine transporter (DAT), and [(3)H]serotonin uptake at the serotonin transporter (SERT). Most of these compounds exhibited potent inhibition of DA uptake at VMAT2 in the nanomolar range (Ki=30-70nM). The two most potent analogues, 7 and 14, both exhibited a Ki value of 31nM for inhibition of VMAT2. The lobelane analogue 14, incorporating 4-(2-fluoroethoxy) and 4-hydroxy aromatic substituents, exhibited 96- and 335-fold greater selectivity for VMAT2 versus DAT and SERT, respectively, in comparison to lobelane. Thus, lobelane analogues bearing hydroxyl and fluoroethoxy moieties retain the high affinity for VMAT2 of the parent compound, while enhancing selectivity for VMAT2 versus the plasmalemma transporters.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Hydroxyphenyl lobelane analogues; Dopamine and serotonin transporter; Dopamine uptake; Fluorinated lobelane analogues; Vesicular monoamine transporter-2

Mesh:

Substances:

Year:  2016        PMID: 27080180      PMCID: PMC4977194          DOI: 10.1016/j.bmcl.2016.03.119

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.

Authors:  J F Fischer; A K Cho
Journal:  J Pharmacol Exp Ther       Date:  1979-02       Impact factor: 4.030

3.  Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes.

Authors:  D K Miller; P A Crooks; L P Dwoskin
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

4.  Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

Authors:  Y M Wang; R R Gainetdinov; F Fumagalli; F Xu; S R Jones; C B Bock; G W Miller; R M Wightman; M G Caron
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

5.  Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.

Authors:  C Pifl; H Drobny; H Reither; O Hornykiewicz; E A Singer
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

6.  Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Authors:  Ashish P Vartak; Justin R Nickell; Jaturaporn Chagkutip; Linda P Dwoskin; Peter A Crooks
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine.

Authors:  N Y Liang; C O Rutledge
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

8.  Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Sairam Krishnamurthy; Seth Norrholm; Gabriela Deaciuc; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

9.  Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.

Authors:  Dennis K Miller; Peter A Crooks; Guangrong Zheng; Vladimir P Grinevich; Seth D Norrholm; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2004-04-30       Impact factor: 4.030

10.  Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-10-14       Impact factor: 2.823

View more
  1 in total

1.  Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Emily R Hankosky; Shyam R Joolakanti; Justin R Nickell; Venumadhav Janganati; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2017-10-20       Impact factor: 2.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.